Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 3 | 2026-08-28 | NCT06596252 | |
| Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease | Digestive System Diseases, Nutritional and Metabolic Diseases, celiac disease, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease | Recruiting | Phase 2 | 2026-04-02 | NCT07298343 | |
| Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) | Cholangitis, Sclerosing, Digestive System Diseases, bile duct disorder, biliary tract disorder, cholangitis, primary sclerosing cholangitis | Not yet recruiting | Phase 3 | 2025-03-20 | NCT06886360 |